Xiaofei Zhou

List of Publications by Year
in descending order

24	624	840776 11	642732 23
papers	citations	h-index	g-index

24	24	24	897
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Assessment of Effects of Investigational TAKâ€931, an Oral Cell Division Cycle 7 Kinase Inhibitor on the QTc Intervals in Patients With Advanced Solid Tumors. Clinical Pharmacology in Drug Development, 2022, , .	1.6	2
2	Metabolism and Disposition of [¹⁴C]Pevonedistat, a First-In-Class NEDD8â€'Activating Enzyme Inhibitor, After Intravenous Infusion to Patients With Advanced Solid Tumors . Drug Metabolism and Disposition, 2022, , DMD-AR-2022-000842.	3.3	1
3	Phase I study assessing the mass balance, pharmacokinetics, and excretion of [14C]-pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors. Investigational New Drugs, 2021, 39, 488-498.	2.6	15
4	Asiaâ€inclusive global development of pevonedistat: Clinical pharmacology and translational research enabling a phase 3 multiregional clinical trial. Clinical and Translational Science, 2021, 14, 1069-1081.	3.1	9
5	Population Pharmacokinetics and Exposureâ€Safety Relationships of Alisertib in Children and Adolescents With Advanced Malignancies. Journal of Clinical Pharmacology, 2021, , .	2.0	3
6	Biotransformation Pathways and Metabolite Profiles of Oral [14C]Alisertib (MLN8237), an Investigational Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors. Drug Metabolism and Disposition, 2020, 48, 217-229.	3.3	11
7	Population pharmacokinetics of pevonedistat alone or in combination with standard of care in patients with solid tumours or haematological malignancies. British Journal of Clinical Pharmacology, 2019, 85, 2568-2579.	2.4	13
8	Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib in Adult Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Dysfunction. Journal of Clinical Pharmacology, 2019, 59, 1204-1215.	2.0	3
9	Effect of CYP3A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours. British Journal of Clinical Pharmacology, 2019, 85, 1464-1473.	2.4	9
10	Mass balance, routes of excretion, and pharmacokinetics of investigational oral [14C]-alisertib (MLN8237), an Aurora A kinase inhibitor in patients with advanced solid tumors. Investigational New Drugs, 2019, 37, 666-673.	2.6	5
11	Effects of rifampin, itraconazole and esomeprazole on the pharmacokinetics of alisertib, an investigational aurora a kinase inhibitor in patients with advanced malignancies. Investigational New Drugs, 2018, 36, 248-258.	2.6	16
12	Global population pharmacokinetics of the investigational Aurora A kinase inhibitor alisertib in cancer patients: rationale for lower dosage in Asia. British Journal of Clinical Pharmacology, 2018, 84, 35-51.	2.4	13
13	Effect of alisertib, an investigational aurora a kinase inhibitor on the QTc interval in patients with advanced malignancies. Investigational New Drugs, 2018, 36, 240-247.	2.6	5
14	Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors. Drugs in R and D, 2016, 16, 45-52.	2.2	10
15	Dose selection for the investigational anticancer agent alisertib (MLN8237): Pharmacokinetics, pharmacodynamics, and exposureâ€"safety relationships. Journal of Clinical Pharmacology, 2015, 55, 336-347.	2.0	27
16	Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose. Investigational New Drugs, 2015, 33, 942-953.	2.6	27
17	Relative bioavailability of a prototype oral solution of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors. International Journal of Clinical Pharmacology and Therapeutics, 2015, 53, 563-572.	0.6	8
18	Phase I study of MLN8237â€"investigational Aurora A kinase inhibitorâ€"in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia. Investigational New Drugs, 2014, 32, 489-499.	2.6	67

#	Article	IF	Citations
19	Phase II Study of Alisertib, a Selective Aurora A Kinase Inhibitor, in Relapsed and Refractory Aggressive B- and T-Cell Non-Hodgkin Lymphomas. Journal of Clinical Oncology, 2014, 32, 44-50.	1.6	185
20	Translational Exposureâ€“Efficacy Modeling to Optimize the Dose and Schedule of Taxanes Combined with the Investigational Aurora A Kinase Inhibitor MLN8237 (Alisertib). Molecular Cancer Therapeutics, 2014, 13, 2170-2183.	4.1	29
21	Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: Phase 1 dose-escalation study. Investigational New Drugs, 2014, 32, 1181-1187.	2.6	34
22	Abstract B216: Mass balance, routes of excretion and pharmacokinetics of investigational oral [14C]alisertib (MLN8237) in patients with advanced solid tumors or lymphoma.. Molecular Cancer Therapeutics, 2013, 12, B216-B216.	4.1	4
23	Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Gynecologic Oncology, 2012, 127, 63-69.	1.4	128
24	Clinical pharmacologic considerations for the phase II/III dose/regimen of the investigational AuroraÂA kinase (AAK) inhibitor MLN8237 (alisertib): Pharmacokinetics (PK), pharmacodynamics (PD), and exposure-safety relationships.. Journal of Clinical Oncology, 2012, 30, 2597-2597.	1.6	0